Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma

BACKGROUND: Adding metronomic capecitabine to concurrent chemoradiotherapy (CCRT) brings failure-free survival (FFS) benefits to patients with locoregionally advanced nasopharyngeal carcinoma (NPC). This study assesses the cost-effectiveness of metronomic capecitabine in locoregionally advanced NPC....

Descripción completa

Detalles Bibliográficos
Autores principales: She, Longjiang, Tian, Kun, Han, Jiaqi, Zuo, Weihan, Wang, Zhu, Zhang, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513587/
https://www.ncbi.nlm.nih.gov/pubmed/36176384
http://dx.doi.org/10.3389/fonc.2022.904372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513587/
https://www.ncbi.nlm.nih.gov/pubmed/36176384
http://dx.doi.org/10.3389/fonc.2022.904372

Ejemplares similares